Competition
Competition — Who Can Hurt Supreme, and Who It Can Beat
Figures converted from GBP at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.
Competitive Bottom Line
Supreme has a real but narrow moat: it is the only UK-listed company running a vertically integrated, multi-category, value-channel branded FMCG platform — manufacturing, brand-licensing, brand-owning, and distributing simultaneously through one Manchester hub into ~3,300 trade accounts across grocery, variety-discount, convenience, cash-and-carry and export. The defensible asset is the system, not any single product: pull out vaping or sports nutrition individually and larger or sharper players win on brand and scale. The competitor that matters most is Imperial Brands — not because IMB will displace Supreme on a B&M shelf, but because IMB's blu (UK vape share above 10%) and its pricing behaviour around the 1 October 2026 vape duty set the wholesale margin Supreme's profit engine resolves to.
The Right Peer Set
Supreme's peer problem is that no public company looks like it. The five peers used here cover Supreme by economic exposure, not by index basket: NICL is the soft-drinks pure-play, APN the sports-nutrition pure-play, IMB the vape category benchmark, PFD the closest multi-category UK branded FMCG template, and HFG the broad UK-FMCG-to-retail channel reference (weakest direct overlap, retained for breadth). All five report in GBP. Fiscal year-ends differ (SUP March, NICL Dec, PFD March, IMB Sep, APN July, HFG Dec) so cross-period reads need fiscal alignment.
Market caps and EVs as of 2026-05-08 (HFG patched manually 2026-04-30 from public web; net debt unavailable from source so EV shown as N/A). Latest FY revenue uses each peer's FY2025 reporting period, converted at period-end GBP/USD rate. Source: peer Fiscal.ai snapshots, peer FY2025 annual reports, peer_valuations.json.
Why this peer set is right. No single company spans Supreme's three categories, so a single-peer multiple is meaningless. NICL covers the soft-drinks economics (asset-light bottling, brand-driven, 46% GM). APN covers the sports-nutrition economics (single-factory, 27% EBITDA margin, 47% UK growth). IMB sets the vape-category framework (regulation, NGP scale, blu UK share >10%). PFD shows what a mature, multi-category UK branded FMCG platform looks like at scale. HFG is the deliberate negative control — a $5.7bn revenue UK-FMCG-to-retail business with 4% EBITDA margin and a single customer (Tesco) that takes 33% of revenue, illustrating the alternative customer-concentration risk Supreme is actively trying to avoid.
Rejected and why: AG Barr (BAG) — strong UK soft-drinks comp but redundant given NICL covers Vimto/squash/RTD. PZ Cussons (PZC) — strong UK FMCG personal care/household fit, but Fiscal.ai 404'd; IR-site-only stage deferred. Britvic (BVIC) — acquired by Carlsberg in 2025, no longer listed. Science in Sport (SIS) — micro-cap with persistent losses, less informative than APN. McBride (MCB) — UK private-label cleaning, economics diverge from Supreme's branded-distribution model.
Where The Company Wins
Four concrete advantages stand up against this peer set, each with a measurable signature.
The platform-economics advantage is the headline takeaway. Supreme's 31.9% blended gross margin is well above IMB (21.8%) and PFD (38.2%, but on much larger asset base) — and within striking distance of NICL/APN — while it is doing four times as many things at once. The honest read: SUP is not best-in-class on any single category, but no peer can match the breadth of categories run at SUP's gross-margin level on its $39m PP&E base.
Where Competitors Are Better
Supreme's peer set highlights four real weaknesses. None is fatal; together they are the reason the rerating gap to NICL/APN multiples may not close on its own.
The honest summary of the weakness column: Supreme is a platform, not a brand. APN, NICL and PFD make more per pound of revenue because each does one thing very well; IMB has scale; HFG has long-term retailer contracts. Supreme's defence is that doing four things passably is harder to copy than doing one thing brilliantly — but that defence has to be re-earned every year through continued M&A integration and category mix discipline.
Threat Map
The two High-severity threats both run through vaping. A duty pass-through failure (1 Oct 2026) and a Chinese-importer disintermediation (12-24 months) attack the same $60m of FY25 vape gross profit from different directions. Mitigating both requires Supreme to (i) hold or grow vape gross margin above 30% post-duty, and (ii) accelerate the Drinks & Wellness rotation faster than the vape risk crystallises. The Medium-severity threats (APN, NICL, PFD) are slower-moving but cumulative — they erode the rerating case rather than break it.
Moat Watchpoints
These are the five measurable signals that will tell an investor whether Supreme's competitive position is improving, holding, or deteriorating over the next 12-24 months. Each is observable in a public filing or industry data source.
The shortest possible competitive read. Supreme is the only UK-listed player with the platform breadth its strategy describes — and the smallest player in every individual category. The moat is breadth, not depth. The H1 FY27 vape-margin print and the Drinks & Wellness gross-margin trajectory are the two numbers that test whether Supreme has graduated from vape-cycle bet to defensible multi-category platform, or whether the rerating gap is an honest discount for being the smallest in its peer set.